CenterBook Partners’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

CenterBook Partners’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-13,702	Closed	-$1.47M	–	507
2023 Q1	$1.47M	Buy	+13,702	New	+$1.58M	0.21%	160

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

CenterBook Partners's RXDX Position: Q2 2023 in Review

CenterBook Partners sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 13,702 shares — an estimated $1.47M sold.

CenterBook Partners first reported a position in RXDX in Q1 2023 and held it in 1 quarter. The position peaked at $1.47M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

CenterBook Partners reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
CenterBook Partners sold 13,702 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $1.47M.
CenterBook Partners first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
CenterBook Partners's Prometheus Biosciences, Inc. Common Stock position peaked at $1.47M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on CenterBook Partners's 13F filing for Q2 2023, filed 14 Aug 2023.